Investor in venture, growth and buyout capital, we have already supported a lot of companies for more than 15 years.
DiscoverAbout
The Turenne Group has been present in the Rhône-Alpes-Auvergne region since 2014.
Over the last 15 years, as an investor specialising in venture capital, growth capital and buyout capital, we have worked in the region with a number of regional companies, such as Alizé Pharma (biotech), Aston Medical (implantology), Biom’up (biotech), Eyetechcare (ultrasound glaucoma treatment), Menix (protheses), Sword (IT consulting) and Axemble (product lifecycle management solutions integrator).
REGIONAL PRESENCE
- Investments in innovative and fast-growing SMEs in the Auvergne-Rhône-Alpes region
- Investments in partnership with our sector teams
FROM VENTURE CAPITAL TO BUYOUT CAPITAL
Our team in Lyon provides venture, growth and buyout capital to companies in the region.
We acquire minority and majority stakes with ticket sizes of €1 million to €10 million with the Group’s sector funds. Our types of investment are as follows:
- Venture capital:
Financing innovative start-ups and SMEs in the Auvergne-Rhône-Alpes region presenting strong growth potential and since 2014, the Turenne Group’s Healthcare team in Lyon has advised SCR (French venture capital company or “Société de Capital Risque”) Sham Innovation Santé, a subsidiary of Sham (part of mutualist group Relyens), dedicated to investing in innovative companies with a particular focus on life sciences. - Growth capital:
Financing the development of businesses that have already reached a certain stage of maturity (primarily through organic growth and acquisitions) - Buyout capital /
Capital restructuring:
Buyouts of the holdings of selling shareholders, diversification of assets owned by executives - Mixed growth capital and capital restructuring transactions
Sham Innovation Santé
Created in July 2014, Sham Innovation Santé is an SCR (French venture capital company or “Société de Capital Risque”), a subsidiary of Sham (part of mutualist group Relyens), advised by the Turenne Group since May 2014 and dedicated to investment in innovative companies, particularly in biotech and medical devices.
Latest news
